Physician profile
Binh V Pham
NPI 1558371559
$22,727.68
in general payments reported to CMS, 2019-2025
46 companies · $3,555 in 2025
The $3,555 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,795 · 2020: $1,785 · 2021: $3,199 · 2022: $2,707 · 2023: $3,004 · 2024: $2,682 · 2025: $3,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,228 · Education: $13.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,227.64 |
| Education | $13.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,994.04 | 2019-2025 | Exalt Model D, Resolution 360 Clip, Overstitch Nxt Endoscopic Suturing System |
| Abbvie INC. | $4,565.45 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,921.39 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,258.54 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Lumendi LLC | $868.36 | 2020-2021 | |
| Ambu INC. | $670.61 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $646.90 | 2021-2025 | Tremfya |
| Genzyme Corporation | $634.95 | 2022-2025 | |
| Gilead Sciences, INC. | $588.52 | 2019-2025 | |
| Janssen Biotech, INC. | $569.35 | 2019-2025 | Stelara, Tremfya, Simponi |
| Lilly USA, LLC | $538.32 | 2024-2025 | Omvoh |
| Cook Medical LLC | $535.01 | 2019-2022 | |
| Pfizer INC. | $490.31 | 2019-2025 | |
| Celgene Corporation | $435.94 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $394.59 | 2022-2025 | Sucraid, Sucraid |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $313.16 | 2022-2025 | Ibsrela |
| Covidien LP | $272.92 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $251.68 | 2024-2025 | Zenpep, Vowst |
| Intercept Pharmaceuticals, INC. | $233.73 | 2019-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $224.37 | 2019-2024 | Linzess |
| Redhill Biopharma INC. | $221.48 | 2021-2023 | Talicia |
| Regeneron Healthcare Solutions, INC. | $218.51 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $207.81 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $149.90 | 2025 | Rezdiffra |
| Romark Laboratories, Lc | $148.43 | 2019-2020 | |
| Shire North American Group INC | $142.02 | 2019 | |
| Apollo Endosurgery US INC | $134.57 | 2022 | |
| Conmed Corporation | $119.31 | 2021 | |
| Daiichi Sankyo INC. | $113.58 | 2019-2022 | |
| Axonics, INC. | $111.30 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $109.09 | 2023 | Zeposia |
| Olympus America INC. | $95.21 | 2022-2023 | Endoclot Phs, High Definition Lcd Monitor |
| Ipsen Biopharmaceuticals, INC | $94.47 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $74.03 | 2023-2024 | Dificid |
| Organon LLC | $73.35 | 2023-2025 | Hadlima, Renflexis |
| Braintree Laboratories, INC. | $61.40 | 2022-2024 | Sutab, Suflave |
| Medtronic, INC. | $51.40 | 2025 | Dragonfly Pancreaticobiliary Scope and Instrument Channel Caps |
| Olympus Corporation of The Americas | $46.58 | 2019 | |
| Allergan, INC. | $31.99 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.36 | 2023 | Onpattro |
| Ferring Pharmaceuticals INC. | $27.02 | 2023-2024 | Rebyota |
| Vivus LLC | $17.74 | 2021 | |
| Alfasigma USA, INC. | $14.94 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.34 | 2023 | |
| Phathom Pharmaceuticals, INC. | $12.71 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binh Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.